Sanjay Basu1, Ryan G Wagner2, Ronel Sewpaul3, Priscilla Reddy3, Justine Davies4. 1. Center for Primary Care and Outcomes Research, Department of Medicine, Palo Alto, CA, USA; Department of Health Research and Policy, Palo Alto, CA, USA; Center for Population Health Sciences, Stanford University, Palo Alto, CA, USA; Center for Primary Care, Harvard Medical School, Boston, MA, USA. Electronic address: basus@stanford.edu. 2. MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Umeå Centre for Global Health Research, Umeå University, Umeå, Sweden. 3. Population Health, Health Systems & Innovation (PHHSI) Human Sciences Research Council (HSRC), Cape Town, South Africa. 4. MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Institute for Applied Health Research, Birmingham University, Birmingham, UK.
Abstract
BACKGROUND: Cardiovascular diseases and their risk factors-particularly hypertension, dyslipidaemia, and diabetes-have become an increasing concern for middle-income countries. Using newly available, nationally representative data, we assessed how cardiovascular risk factors are distributed across subpopulations within South Africa and identified which cardiovascular treatments should be prioritised. METHODS: We created a demographically representative simulated population for South Africa and used data from 17 743 respondents aged 15 years or older of the 2012 South African National Health and Nutrition Examination Survey (SANHANES) to assign information on cardiovascular risk factors to each member of the simulated population. We created a microsimulation model to estimate the health and economic implications of two globally recognised treatment recommendations: WHO's package of essential non-communicable disease interventions (PEN) and South Africa's Primary Care 101 (SA PC 101) guidelines. The primary outcome was total disability-adjusted life-years (DALYs) averted through treatment of all cardiovascular disease or microvascular type 2 diabetes complications per 1000 population. We compared outcomes at the aspirational level of achieving access to treatment among 70% of the population. FINDINGS: Based on the SANHANES data, South Africans had a high prevalence of hypertension (24·8%), dyslipidaemia (17·5%), and diabetes (15·3%). Prevalence was disproportionately high and treatment low among male, black, and poor populations. Our simulated population experienced a burden of 40·0 DALYs (95% CI 29·5-52·0) per 1000 population per year from cardiovascular disease or type 2 diabetes complications at current treatment levels, which lowered to 32·9 DALYs (24·4-44·7) under WHO PEN implementation and to 32·5 (24·4-44·8) under SA PC 101 implementation. Under both guidelines, there were increases in blood pressure treatment (4·2 percentage points under WHO PEN vs 12·6 percentage points under SA PC 101), lipid treatment (16·0 vs 14·9), and glucose control medications (1·2 vs 0·6). The incremental cost-effectiveness of implementing SA PC 101 over current treatment would be a saving of US$24 902 (95% CI 14 666-62 579) per DALY averted compared with a saving of $17 587 (1840-42 589) under WHO PEN guidelines. INTERPRETATION: Cardiovascular risk factors are common and disproportionate among disadvantaged populations in South Africa. Treatment with blood pressure agents and statins might need greater prioritisation than blood glucose therapies, which contrasts with observed treatment levels despite a lower monthly cost of blood pressure or statin treatment than of sulfonylurea or insulin treatment. FUNDING: Stanford University.
BACKGROUND:Cardiovascular diseases and their risk factors-particularly hypertension, dyslipidaemia, and diabetes-have become an increasing concern for middle-income countries. Using newly available, nationally representative data, we assessed how cardiovascular risk factors are distributed across subpopulations within South Africa and identified which cardiovascular treatments should be prioritised. METHODS: We created a demographically representative simulated population for South Africa and used data from 17 743 respondents aged 15 years or older of the 2012 South African National Health and Nutrition Examination Survey (SANHANES) to assign information on cardiovascular risk factors to each member of the simulated population. We created a microsimulation model to estimate the health and economic implications of two globally recognised treatment recommendations: WHO's package of essential non-communicable disease interventions (PEN) and South Africa's Primary Care 101 (SA PC 101) guidelines. The primary outcome was total disability-adjusted life-years (DALYs) averted through treatment of all cardiovascular disease or microvascular type 2 diabetes complications per 1000 population. We compared outcomes at the aspirational level of achieving access to treatment among 70% of the population. FINDINGS: Based on the SANHANES data, South Africans had a high prevalence of hypertension (24·8%), dyslipidaemia (17·5%), and diabetes (15·3%). Prevalence was disproportionately high and treatment low among male, black, and poor populations. Our simulated population experienced a burden of 40·0 DALYs (95% CI 29·5-52·0) per 1000 population per year from cardiovascular disease or type 2 diabetes complications at current treatment levels, which lowered to 32·9 DALYs (24·4-44·7) under WHO PEN implementation and to 32·5 (24·4-44·8) under SA PC 101 implementation. Under both guidelines, there were increases in blood pressure treatment (4·2 percentage points under WHO PEN vs 12·6 percentage points under SA PC 101), lipid treatment (16·0 vs 14·9), and glucose control medications (1·2 vs 0·6). The incremental cost-effectiveness of implementing SA PC 101 over current treatment would be a saving of US$24 902 (95% CI 14 666-62 579) per DALY averted compared with a saving of $17 587 (1840-42 589) under WHO PEN guidelines. INTERPRETATION: Cardiovascular risk factors are common and disproportionate among disadvantaged populations in South Africa. Treatment with blood pressure agents and statins might need greater prioritisation than blood glucose therapies, which contrasts with observed treatment levels despite a lower monthly cost of blood pressure or statin treatment than of sulfonylurea or insulin treatment. FUNDING: Stanford University.
Authors: David Flood; Jacqueline A Seiglie; Matthew Dunn; Scott Tschida; Michaela Theilmann; Maja E Marcus; Garry Brian; Bolormaa Norov; Mary T Mayige; Mongal Singh Gurung; Krishna K Aryal; Demetre Labadarios; Maria Dorobantu; Bahendeka K Silver; Pascal Bovet; Jutta M Adelin Jorgensen; David Guwatudde; Corine Houehanou; Glennis Andall-Brereton; Sarah Quesnel-Crooks; Lela Sturua; Farshad Farzadfar; Sahar Saeedi Moghaddam; Rifat Atun; Sebastian Vollmer; Till W Bärnighausen; Justine I Davies; Deborah J Wexler; Pascal Geldsetzer; Peter Rohloff; Manuel Ramírez-Zea; Michele Heisler; Jennifer Manne-Goehler Journal: Lancet Healthy Longev Date: 2021-05-21
Authors: Brian Godman; Debashis Basu; Yogan Pillay; Julius C Mwita; Godfrey Mutashambara Rwegerera; Bene D Anand Paramadhas; Celda Tiroyakgosi; Patrick Mbah Okwen; Loveline Lum Niba; Justice Nonvignon; Israel Sefah; Margaret Oluka; Anastasia N Guantai; Dan Kibuule; Francis Kalemeera; Mwangana Mubita; Joseph Fadare; Olayinka O Ogunleye; Larry A Distiller; Enos M Rampamba; Jeffrey Wing; Debjani Mueller; Abubakr Alfadl; Adefolarin A Amu; Zinhle Matsebula; Aubrey Kalungia; Trust Zaranyika; Nyasha Masuka; Janney Wale; Ruaraidh Hill; Amanj Kurdi; Angela Timoney; Stephen Campbell; Johanna C Meyer Journal: Front Pharmacol Date: 2020-03-20 Impact factor: 5.810
Authors: Andrew Fraser; Jessica Newberry Le Vay; Peter Byass; Stephen Tollman; Kathleen Kahn; Lucia D'Ambruoso; Justine I Davies Journal: BMJ Glob Health Date: 2020-04-16
Authors: Justine I Davies; Sumithra Krishnamurthy Reddiar; Lisa R Hirschhorn; Cara Ebert; Maja-Emilia Marcus; Jacqueline A Seiglie; Zhaxybay Zhumadilov; Adil Supiyev; Lela Sturua; Bahendeka K Silver; Abla M Sibai; Sarah Quesnel-Crooks; Bolormaa Norov; Joseph K Mwangi; Omar Mwalim Omar; Roy Wong-McClure; Mary T Mayige; Joao S Martins; Nuno Lunet; Demetre Labadarios; Khem B Karki; Gibson B Kagaruki; Jutta M A Jorgensen; Nahla C Hwalla; Dismand Houinato; Corine Houehanou; David Guwatudde; Mongal S Gurung; Pascal Bovet; Brice W Bicaba; Krishna K Aryal; Mohamed Msaidié; Glennis Andall-Brereton; Garry Brian; Andrew Stokes; Sebastian Vollmer; Till Bärnighausen; Rifat Atun; Pascal Geldsetzer; Jennifer Manne-Goehler; Lindsay M Jaacks Journal: PLoS Med Date: 2020-11-10 Impact factor: 11.069